Publication Name	World Journal of Gastroenterology
Manuscript ID	112719
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Cohort Study
Article Title	Retreatment hepatitis B surface antigen clearance prediction model identifies pegylated interferon alpha candidates in chronic hepatitis B
Manuscript Source	Unsolicited Manuscript
All Author List	Yan-Chao Fu, Jun Li, Jia-Yin Wang, Yi-Wen Zhang, Fei Yan, Jing Chen, Qin Du, Chao Yang, Jing Liang, Qing Ye and Hui-Ling Xiang
Funding Agency and Grant Number	Funding Agency Grant Number Tianjin Health Research Project (Key Project) No. TJWJ2024ZD004 Tianjin Key Medical Discipline (Specialty) Construction Project No. TJYXZDXK-034A
Corresponding Author	Hui-Ling Xiang, Department of Gastroenterology and Hepatology, Tianjin University Central Hospital (Tianjin Third Central Hospital), Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, No. 83 Jintang Road, Hedong District, Tianjin 300170, China. huilingxiang@163.com
Key Words	Chronic hepatitis B; Retreatment; Pegylated interferon alpha; Hepatitis B surface antigen clearance; Prediction model
Core Tip	This pioneering study developed the first predictive model (retreatment hepatitis B surface antigen clearance prediction score) for hepatitis B surface antigen clearance during pegylated interferon retreatment in chronic hepatitis B. Analyzing 135 patients, we found that retreatment candidates scoring ≥ 110 points achieved dramatically higher clearance rates (81% vs 3.45% in low-scorers). Key predictors included pegylated interferon monotherapy, substantial initial hepatitis B surface antigen decline, extended treatment intervals, and lower retreatment baseline hepatitis B surface antigen. The model enables precision selection to avoid futile therapy in 97% of non-responders.
Citation	Fu YC, Li J, Wang JY, Zhang YW, Yan F, Chen J, Du Q, Yang C, Liang J, Ye Q, Xiang HL. Retreatment hepatitis B surface antigen clearance prediction model identifies pegylated interferon alpha candidates in chronic hepatitis B. World J Gastroenterol 2025; In press

Received	2025-08-05 02:31
Peer-Review Started	2025-08-05 02:32
To Make the First Decision
Return for Revision	2025-09-03 10:06
Revised	2025-09-14 15:57
Second Decision	2025-10-24 02:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-10-24 06:12
Articles in Press	2025-10-24 06:12
Publication Fee Transferred	2025-09-15 14:50
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com